Valuation: Zai Lab Limited

Market Cap 2.24B 1.96B 1.81B 1.68B 3.18B 214B 3.23B 21.69B 8.5B 105B 8.43B 8.25B 364B P/E 2026 *
-9.02x
P/E 2027 * -10.7x
Enterprise Value 1.8B 1.58B 1.45B 1.34B 2.55B 172B 2.6B 17.41B 6.82B 84.45B 6.76B 6.62B 293B EV / Sales 2026 *
4.02x
EV / Sales 2027 * 3.12x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week+4.82%
Current month+4.82%
1 month+20.83%
3 months-1.69%
6 months+9.43%
Current year+17.57%
1 week 16.2
Extreme 16.2
17.7
1 month 13.9
Extreme 13.9
17.7
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
146
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%+2.38%-42.38%-33.59% 2.22B
+0.76%+2.09%+20.88%-3.54% 67.44B
+0.52%-5.52%+46.80%+219.12% 53.98B
-2.79%+32.50%+32.50%+32.50% 41.77B
-2.59%+0.46%-49.52%-53.67% 41.15B
-0.72%-7.96%+49.53%-27.69% 29.58B
+3.74%-4.01%+133.49%-35.59% 29.28B
+1.07%+1.42%+72.47%+90.95% 23.43B
+1.22%-0.06%+9.35%+194.96% 19.11B
+1.14%-0.17%+68.83%+135.40% 16.82B
Average +0.31%-0.52%+34.19%+51.88% 35.84B
Weighted average by Cap. +0.07%-1.05%+35.62%+52.15%

Financials

2026 *2027 *
Net sales 449M 393M 362M 335M 636M 42.83B 646M 4.33B 1.7B 21.03B 1.68B 1.65B 72.85B 596M 521M 480M 445M 844M 56.85B 858M 5.75B 2.26B 27.92B 2.24B 2.19B 96.7B
Net income -241M -211M -194M -180M -341M -22.99B -347M -2.33B -912M -11.29B -904M -885M -39.11B -156M -137M -126M -117M -222M -14.94B -225M -1.51B -593M -7.33B -587M -575M -25.4B
Net Debt -443M -388M -357M -331M -628M -42.3B -638M -4.28B -1.68B -20.77B -1.66B -1.63B -71.95B -387M -339M -312M -289M -549M -36.96B -558M -3.74B -1.47B -18.15B -1.45B -1.42B -62.87B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
09/07/26 €17.40 +1.16%
08/07/26 €17.20 +1.78%
07/07/26 €16.90 +1.81%
06/07/26 €16.60 +0.61%
03/07/26 €16.50 -0.60%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
19.98USD
Average target price
33.30USD
Spread / Average Target
+66.68%

Quarterly revenue - Rate of surprise